Subgroup Analyses and Overall HRQoL From Phase III TAGS: Trifluridine/Tipiracil vs Placebo in Previously Treated Gastric/GEJ Adenocarcinoma

May 31 - June 4, 2019; Chicago, Illinois
Survival outcomes with trifluridine/tipiracil in patients aged ≥ 65 years or those with metastatic GEJ cancer were generally consistent with the overall patient population, and HRQoL outcomes were stable over time in the overall population.
Format: Microsoft PowerPoint (.ppt)
File Size: 235 KB
Released: June 11, 2019

Acknowledgements

Provided by the USF Health

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This activity is supported by educational grants from
Blueprint Medicines
Celgene Corporation
Taiho Oncology Inc.

Related Content

Global perspectives of key novel combination studies presented at ASCO 2021 from international experts in solid tumors from Clinical Care Options (CCO)

person default Dirk Arnold, MD, PhD Prof Isabelle Ray-Coquard, MD, PhD Egbert F. Smit, MD, PhD Released: August 5, 2021

Slides from Clinical Care Options (CCO) on biomarker testing to guide targeted therapy for gastrointestinal cancer

Allison M. Cushman-Vokoun, MD, PhD John L. Marshall, MD Released: August 5, 2021

Video of a live Clinical Care Options (CCO) webinar on immune checkpoint inhibitors for HCC and other hepatobiliary cancers

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: July 27, 2021 Expired: July 26, 2022

Expert review of key data in GI cancers from the 2021 ASCO annual meeting, from Clinical Care Options (CCO)

Manish A. Shah, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: July 27, 2021 Expired: July 26, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue